Dr. Andre R. Kydd
@DrAndreKydd
Followers
213
Following
175
Media
25
Statuses
148
NIH/NCI Hem/Onc Fellow starting July 2022| UGSP/iCURE Alum| GU cancers (NIH GU w Andrea Apolo) , cancer epigenetics| Views = my own
Bethesda, MD
Joined August 2021
RT @JournalCancer: The outlook for the #BladderCancer field is undoubtedly positive as the field builds upon an excellent foundation of nov….
0
13
0
RT @tompowles1: Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active s….
0
78
0
Proud to share our latest on recent advances and progress in treating Bladder Cancer with the @apolo_andrea group! @SaadAtiq24 @NicholasISimon @EliasChandran @nciccr_gmb.
acsjournals.onlinelibrary.wiley.com
This review highlights the top advances in nonmuscle-invasive, muscle-invasive, and metastatic bladder cancer over the past year. The outlook for the field is undoubtedly positive as the field...
1
6
14
RT @yekeduz_emre: A striking wrap-up by @apolo_andrea and team:. 2024’s top 5 advances in #BladderCancer: .1️⃣TAR-200 intravesical drug del….
0
31
0
RT @UroDocAsh: The future of bladder cancer is in great hands. 👏. Stellar class of 2025 John Quale Travel Fellows!.@BladderCancerUS #BCANTT….
0
16
0
Wonderful insights from clinical trials - both positive and negative, with pros and cons- at @BladderCancerUS #bcantt25 co-chaired by @apolo_andrea @nciccr_gmb and Seth Lerner @DrRosenbergMSK @JCensits @Parminder1699
0
8
18
RT @apolo_andrea: #BCANTT25 proud of our Medical Oncology fellow Miles Hsu who received the the 2025 John Quale Travel award for our work i….
0
9
0
RT @apolo_andrea: Yes! Congratulations to all! And a big shout out to our own Miles Hsu @nciccr_gmb @NIH @BladderCancerUS .#EndBladderCancer.
0
3
0
Proud to share this summary from #asco2025, segment on renal, bladder and prostate cancers from @OncBrothers discussion with @drenriquegrande and @PetrosGriv - article co-authored with @SaadAtiq24 .
1
3
6
RT @EliasChandran: Opening soon at the NIH!! E-VIRTUE, A Phase 2 Trial of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitour….
tandfonline.com
Enfortumab vedotin (EV) is an antibody-drug conjugate targeting nectin-4 with a monomethyl auristatin E payload, a potent microtubule inhibitor. It is a standard of care in metastatic or locally ad...
0
10
0
RT @oncodaily: @apolo_andrea @SaadAtiq24 @theNCI @ASCO @carisls @EliasChandran @MattGalsky @NicholasISimon @IBCG_BladderCA @BladderCaJrnl @….
oncodaily.com
Andrea Apolo: Very proud of Saad Atiq for presenting data at ASCO25 / Agnostic Biomarkers, Andrea Apolo, ASCO25, bladder cancer, cancer, fight against cancer,
0
1
0
RT @apolo_andrea: Very proud of our own @SaadAtiq24 @theNCI senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarker….
0
27
0
RT @PTarantinoMD: Results from OptiTROP-B01 out in @NatureMedicine. The TROP2-ADC sacituzumab tirumotecan improved PFS and OS in highly pre….
0
75
0
RT @apolo_andrea: “Outstanding Mentor award” is one of the most important awards I have received. ❤️.Pay it forward! Thank you to my mentee….
open.spotify.com
Inside Cancer Careers · Episode
0
16
0
A video highlighting the work at the @NIH, especially in rare diseases (even beyond cancer!), from the patient perspective. Even more proud that it features the work of my superstar wife @DrCaroMontano with Hopkins mentor Nara Sobreira
instagram.com
0
0
2
RT @DrChoueiri: Dr @apolo_andrea @theNCI has executed phenomenal innovative investigator-initiated clinical trials in rare GU/Bladder Canc….
0
13
0
Sharing this @BladderCancerUS BCAN Survey for bladder cancer patients!.
As our first 'effort' it is our privilege to announce the BCAN 2025 New Faces of Bladder Cancer Survey. The survey aims to understand the needs, challenges, and experiences of patients across all ages and stages of urothelial cancer. The insights will guide future resources,
0
0
3
RT @DavidBenjaminMD: Is it time to re-classify urachal cancer as a GI rather than a GU malignancy?. In @Nature_NPJ Precision Oncology, we s….
0
18
0
Honored to help nominate @apolo_andrea as an excellent mentor and sponsor on our career paths!.
0
1
7
RT @OncLive: Sacituzumab govitecan has received a breakthrough therapy designation by the @US_FDA for patients with extensive-stage SCLC in….
onclive.com
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
0
7
0